JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1010/0.01/17.01.25 Share Price

Warrant

DE000JL05S84

Real-time Bid/Ask 05:16:09 05/07/2024 pm IST
0.96 EUR / 1 EUR +1.03% Intraday chart for JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1010/0.01/17.01.25
Current month-15.65%
1 month+27.63%
Date Price Change
05/24/05 0.97 0.00%
04/24/04 0.97 -11.82%
03/24/03 1.1 -6.78%
02/24/02 1.18 -1.67%
01/24/01 1.2 +4.35%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:28 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
Issuer J.P. Morgan
WKN JL05S8
ISINDE000JL05S84
Date issued 12/04/2023
Strike 1,010 $
Maturity 17/01/2025 (196 Days)
Parity 100 : 1
Emission price 0.79
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.28
Lowest since issue 0.34
Delta0.62x
Omega 6.013
Premium8.98x
Gearing9.65x
Moneyness 1.014
Difference Strike -14.09 $
Difference Strike %-1.40%
Spread 0.04
Spread %4.00%
Theoretical value 0.9800
Implied Volatility 28.22 %
Total Loss Probability 45.76 %
Intrinsic value 0.1302
Present value 0.8498
Break even 1,116.08 €
Theta-0.02x
Vega0.03x
Rho0.03x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,024 USD
Average target price
1,051 USD
Spread / Average Target
+2.67%
Consensus